Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor
Abstract Background Type 2 diabetes mellitus has become one of the most important public health concerns worldwide. Due to its high prevalence and morbidity, there is an avid necessity to find new therapies that slow the progression and promote the regression of the disease. Imatinib mesylate is a t...
Main Authors: | Miguel Ángel Gómez-Sámano, Jorge Enrique Baquerizo-Burgos, Melissa Fabiola Coronel Coronel, Buileng Daniela Wong-Campoverde, Fernando Villanueva-Martinez, Diego Molina-Botello, Jose Alonso Avila-Rojo, Lucía Palacios-Báez, Daniel Cuevas-Ramos, Francisco Javier Gomez-Perez, Alejandro Zentella-Dehesa, Álvaro Aguayo-González, Alfonso Gulias-Herrero |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-11-01
|
Series: | BMC Endocrine Disorders |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12902-018-0303-x |
Similar Items
-
Safety of Regular-Dose Imatinib Therapy in Patients with Gastrointestinal Stromal Tumors Undergoing Dialysis
by: Ryota Niikura, et al.
Published: (2016-05-01) -
Imatinib Mesylate Therapy in Advanced Gastrointestinal Stromal Tumors: Experience from a Single Institute
by: Hui-Hua Hsiao, et al.
Published: (2006-12-01) -
Imatinib-Resistant Gastrointestinal Stromal Tumor Presenting as a Large Abdominal Mass
by: Asim Haider, et al.
Published: (2021-08-01) -
Surgical intervention of a giant gastric gastrointestinal stromal tumor following neoadjuvant therapy with imatinib
by: Chien-Yang Wang, et al.
Published: (2018-01-01) -
SDH-deficient gastrointestinal stromal tumors: paradoxical effect of imatinib
by: Daria A. Filonenko, et al.
Published: (2020-07-01)